Coming soon
Meet Yodatai, your Digital Data Assistant. Learn more and get your early invite now!
エラーが発生しました。 詳細 隠す
保存されていないページがあります。 復元 取り消す

Biotechnology Innovation Organization

BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.

すべてのデータセット:  B E V
  • B
    • 2月 2016
      ソース: Biotechnology Innovation Organization
      アップロード者: Knoema
      以下でアクセス: 03 5月, 2016
      データセットを選択
      Sixth Biennial Report of Battelle and BIO indicate the followings:1. In 2012, U.S. bioscience companies employed 1.62 million personnel across more than 73,000 individual business establishments.2. Over the past decade the industry has added nearly 111,000 new, high-paying jobs or 7.4 percent to its employment base.3. The industry continues its tradition of creating high-wage, family-sustaining jobs with average wages 80 percent greater than the overall private sector and growing at a faster rate.
  • E
  • V
    • 2月 2016
      ソース: Biotechnology Innovation Organization
      アップロード者: Knoema
      以下でアクセス: 02 5月, 2016
      データセットを選択
      Access to early-stage financing is the lifeblood of biotechnology innovation. For therapeutic-focused biotechnology companies in particular, the required capital and development timelines dwarf most other industries, making it challenging to find sizable early investments from committed investors. As the world’s largest trade association representing biotechnology companies across the United States and in more than 30 other nations, it is important for BIO to better understand investor trends in order to determine where scientific or policy issues may be impacting the ability to maintain a robust pipeline of innovative medicines.